Efficacy of Dulaglutide (DU) as First Injectable Option for Patients with Type 2 Diabetes (T2D): A Post Hoc Pooled Analysis

被引：0
|
作者：
Patel, Hiren
Munir, Kashif M.
Sutherland, Sindee S.
Konig, Manige
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-2303-PUB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2303-PUB
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial
    Qifu Li
    Qiqi Zhang
    Rui Wang
    Tianpei Hong
    Diabetes Therapy, 2022, 13 : 161 - 173
  • [22] Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies
    Jian Kuang
    Jiankun Zhu
    Siying Liu
    Quanmin Li
    Diabetes Therapy, 2020, 11 : 2329 - 2339
  • [23] Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis
    Botros, Fady T.
    Gerstein, Hertzel C.
    Malik, Raleigh
    Nicolay, Claudia
    Hoover, Anastasia
    Turfanda, Ibrahim
    Colhoun, Helen M.
    Shaw, Jonathan E.
    DIABETES CARE, 2023, 46 (08) : 1524 - 1530
  • [24] Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial
    Li, Qifu
    Zhang, Qiqi
    Wang, Rui
    Hong, Tianpei
    DIABETES THERAPY, 2022, 13 (01) : 161 - 173
  • [25] Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis
    Zinman, Bernard
    Ahren, Bo
    Neubacher, Dietmar
    Patel, Sanjay
    Woerle, Hans-Juergen
    Johansen, Odd Erik
    CANADIAN JOURNAL OF DIABETES, 2016, 40 (01) : 50 - 57
  • [26] Mechanisms of the Antihyperglycemic Effect of Sitagliptin in Patients with Type 2 Diabetes (T2D)
    Muscelli, Elza
    Casolaro, Arturo
    Gastaldelli, Amalia
    Mari, Andrea
    Seghieri, Giuseppe
    Chen, Yu
    Alba, Maria
    Holst, Jens
    Ferrannini, Ele
    DIABETES, 2011, 60 : A267 - A267
  • [27] Dapagliflozin (DAPA) in Patients with Type 2 Diabetes (T2D) and Mixed Dyslipidemia
    Bays, Harold E.
    Sartipy, Peter
    Xu, John
    Langkilde, Anna Maria
    Sjostrom, C. David
    DIABETES, 2016, 65 : A306 - A306
  • [28] Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes (T2D): Outcomes by Body Mass Index (BMI)
    Shatskov, Alla
    Rezvani, Geoffrey
    Mansfield, Traci
    DIABETES, 2016, 65 : A299 - A299
  • [29] Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial
    Raubenheimer, Peter J.
    Cushman, William C.
    Avezum, Alvaro
    Basile, Jan
    Conget, Ignacio
    Dagenais, Gilles
    Hoover, Anastasia
    Jansky, Petr
    Lanas, Fernando
    Leiter, Lawrence A.
    Lopez-Jaramillo, Patricio
    Pogosova, Nana
    Probstfield, Jeffrey
    Rao-Melacini, Purnima
    Ryden, Lars
    Sheu, Wayne H-H
    Temelkova-Kurktschiev, Theodora
    Gerstein, Hertzel C.
    DIABETES OBESITY & METABOLISM, 2022, 24 (04): : 704 - 712
  • [30] REAL-WORLD ECONOMIC OUTCOMES AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) TREATED WITH DULAGLUTIDE (DU) VS. BASAL INSULIN (BI) IN THE US: THE DISPEL™ STUDY
    Mody, R.
    Huang, Q.
    Yu, M.
    Zhang, X.
    Wang, L.
    Grabner, M.
    Patel, H.
    VALUE IN HEALTH, 2019, 22 : S149 - S150
12345